Because Notch activity is elevated in HG-treated cancer cells and tissues from HER2-positive breast cancer patients with hyperglycemia, we postulated that hyperglycemia-driven NOTCH activation in breast cancer cells aggravated resistance to HER2-targeted therapy. The gene discussed is ERBB2; the disease is breast cancer.